Small-Caps
Acrow Limited (ASX: ACF): Is This Growing Equipment Rental Business a Buy in Oversold Territory?
Acrow Limited is an Australian engineering and equipment rental company supplying formwork and scaffolding to construction and infrastructure projects. The business generates recurring income from its large hire fleet and has delivered strong revenue growth in recent years. Despite recent share price weakness, it offers solid cash flow and a fully franked dividend yield above 5%.
Racura Oncology Ltd (ASX: RAC): Could RC220 Turn This Small Biotech into a Billion-Dollar Cancer Stock?
Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
Immutep (ASX: IMM): A High-Risk Immunotherapy Bet Waiting for Phase III Validation
Immutep is a Sydney-based clinical-stage biotechnology company focused on immunotherapy, specifically targeting the LAG-3 immune pathway. The company is dual-listed on the ASX and NASDAQ, giving it access to both Australian and US capital markets. It does not yet generate commercial product revenue and remains dependent on capital markets and partnerships to fund its development programs, making it a milestone-driven investment rather than a revenue-backed operating business.
Silver’s On the Move Again: Is Investigator Silver (IVR) Worth Another Look?
Silver has rebounded sharply after a brutal 30–40% pullback, driven by geopolitical tensions and renewed macro uncertainty. Against this backdrop, Investigator Resources Ltd (ASX: IVR) — whose share price has more than tripled over the past year — has pulled back from recent highs as traders de-risk. The key question now is whether silver’s renewed surge signals another leg higher, offering leveraged upside for IVR, or just more short-term volatility.
How much lower could Hot Chili’s (ASX: HCH) recently started downtrend take the share price?
Hot Chili Limited is a pre-revenue copper developer focused on its large-scale Costa Fuego project in Chile, supported by strategic water infrastructure and long-term exposure to the global copper supply deficit theme. However, its recent share price weakness has been driven by a discounted capital raising, ongoing dilution risk, high cash burn, valuation concerns, and broader copper-sector volatility. Technically, the stock has entered a correction phase, with downside support levels around A$1.25–1.30, A$1.15 and near A$1.00, while a sustained break below the A$0.80–0.90 zone would signal a deeper trend reversal.
Most lithium explorers are falling — why is Atlantic Lithium (ASX: A11) holding up, and what does it signal?
Atlantic Lithium is holding up while many lithium explorers fall because it is further advanced toward production, with permitting progress at Ewoyaa, funding support, and improving lithium prices underpinning confidence. Strong drilling results and a clear path to FID differentiate it from early-stage peers. Technically, the stock remains in an uptrend with solid volume support, signalling accumulation rather than distribution and suggesting investors are backing execution, not just sentiment.
Brainchip Holding's (ASX: BRN) downtrend is in full force. How much lower can it go?
Brainchip Holdings (ASX: BRN) is in a clear downtrend, with persistent selling pressure keeping it near lows and preventing sustained gains, as weak technicals and broader tech sector headwinds continue to weigh on the stock.
Atlantic Lithium’s (ASX: A11) uptrend is holding amid heavy market turbulence. How significant is this show of resilience?
Atlantic Lithium has managed to hold its uptrend despite broader market turbulence, a sign of underlying strength in a weak environment for resource stocks. Steady buying at key support levels suggests confidence has not collapsed, supported by progress at its Ewoyaa lithium project in Ghana. This combination of solid fundamentals and constructive chart behaviour highlights resilience in a volatile, sentiment-driven sector.
Appen (ASX: APX) - One of the few AI stocks on the ASX with a currently rising share price
Appen Limited (ASX: APX), founded in 1996 and listed since 2015, is an Australian AI data specialist providing dataset sourcing, annotation, and model evaluation. Operating the Global Services and New Markets segments, it serves major tech clients across multiple industries, leveraging a 1M+ global workforce that spans 180+ languages in 130 countries.
Waratah Mineral (ASX: WTM) has made multiple higher lows. Is it building the base for another leg up?
Waratah Minerals, an Australian gold-copper explorer in NSW, has rebounded strongly from last year’s lows. A clear pattern of higher lows suggests growing accumulation, easing selling pressure and sustained market interest, positioning the stock to potentially break higher if a catalyst emerges.
.webp&w=828&q=75)
How much higher can Korvest (ASX: KOV) share price go after the recent breakout?
Korvest Ltd (ASX: KOV) is a South Australian industrial manufacturer specialising in cable and pipe support systems and corrosion protection services, with earnings linked to infrastructure, resources, energy and industrial activity, as well as ongoing maintenance demand.
How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?
Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.
How Much Higher Can CETTIRE's (ASX: CTT) Share Price Go After the Recent Breakout?
Cettire (ASX: CTT) share price recently had a breakout. But it is in a bit of limbo; enough promise remains that a rebound could be on the cards, but enough uncertainty that it’s far from a safe bet. On one hand, the company is forecast to post healthy earnings-per-share growth over the next few years and has a pretty low price-to-sales ratio compared with peers, suggesting some latent value. On the other hand, consensus analyst targets hover modestly, some even see a drop, and many believe any upside beyond roughly one Australian dollar a share depends on improvements that aren’t guaranteed.
Investigator Silver (ASX: IVR)- Positions for Catalysts Amid Strengthening Silver Market
Investigator Silver (ASX: IVR), formerly known as Investigator Resources, is moving through one of the most strategically important phases in its history. The company is advancing the Paris Silver Project, Australia’s highest-grade undeveloped primary silver deposit, while simultaneously delivering exploration wins across its 100%-owned Peterlumbo tenement and progressing copper-gold targets at Uno Morgans.
Invictus Energy (ASX: IVZ) – A Frontier Play with Optionality
We view Invictus Energy as a rare example of an explorer with a clear pathway to development in one of Africa’s last underexplored rift systems. The Mukuyu gas-condensate discovery in Zimbabwe’s Cabora Bassa Basin anchors the portfolio, while high-impact follow-up at Musuma-1 and a strategic financing partnership with Al Mansour Holdings (AMH) materially de-risk the next stage of value creation.
Embark Early Education (ASX: EVO) Is Offering 6.8% Fully-Franked Dividend Yield, Should You Buy Its Shares?
We see HY2025 as the first genuinely credible step in EVO’s multi-year turnaround. Not a cosmetic clean-up. Not a one-off bounce. A real shift. Occupancy is climbing, labour stability is improving, centre-level margins are widening, and cashflow finally has the shape of something we can underwrite. Management has been making tough decisions — cutting deadweight centres, fixing staffing inconsistencies, and rebuilding trust in local communities — and the P&L now reflects it.
BrainChip Holdings (ASX: BRN): High-Optionality Growth Play
BrainChip is a pioneer in ultra-low-power, neuromorphic AI processing, anchored by its Akida spiking neural network architecture. With US$13.5 million cash as of June 2025, the company is funding aggressive commercialisation efforts, including next-gen Akida 2.0, Pico devices, and defence / edge-AI partnerships. While financial performance is still pre-profit, recent commercial wins, deep IP protection, and product roadmap momentum provide compelling optional upside. Key risks include cash burn, technology adoption, and scaling edge-AI deployments.